Skip to main
  1. Stocks
  2. Ascentage Pharma Group International
  3. Forecast
AAPG

AAPG Stock Forecast & Price Target

AAPG Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ascentage Pharma Group is positioned favorably because its two de-risked commercial anchors, olverembatinib and lisaftoclax, now have broad China reimbursement support, with lisaftoclax added to the 2026 NRDL and both assets’ approved indications covered effective Jan 1, 2027. The company generated $41.6M in product sales in 1H26, while olverembatinib’s NRDL coverage helped drive FY25 revenue of $62.2M, up 81% YoY, underscoring the commercial leverage from reimbursement and hospital formulary expansion. Its outlook is further strengthened by a differentiated apoptosis platform, seven pipeline drug candidates, and multiple catalysts through 2H27, including enrollment completions, ASH data, and potential NDA filings, with cash of $279.4M supporting runway into 2028.

Bears say

Ascentage Pharma Group is viewed negatively because its lead assets appear to face weak differentiation and execution risk: slower adoption in China limits Olverembatinib growth, global studies have not clearly separated it from incumbents, and Lisaftoclax has faced enrollment or regulatory delays that push back commercialization. The company’s Bcl-2 strategy also looks challenged by evidence that venetoclax improved response rates but not overall survival in the registrational Phase 3 VERONA study, while Lisaftoclax’s pharmacokinetic and tolerability advantages may not materially improve dose intensity, treatment duration, or survival. In addition, APG-3288 enters a crowded BTK degrader field with a high safety bar, and the cited sonrotoclax data show substantial hematologic toxicity, infections, dose reductions, and even treatment-emergent deaths, all of which could constrain uptake, pricing power, and investor confidence.

AAPG has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ascentage Pharma Group International and is not a guaranteed prediction by Public.com or investment advice.

AAPG Analyst Forecast & Price Prediction

Get the latest AAPG stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AAPG

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ascentage Pharma Group International (AAPG) Forecast

Analysts have given AAPG a Strong Buy based on their latest research and market trends.

According to 7 analysts, AAPG has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $43.29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $43.29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ascentage Pharma Group International (AAPG)


AAPG Analyst Forecast & Price Prediction

Get the latest AAPG stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AAPG

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AAPG stock data and trends